Combination chemotherapy withy CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (mitoxantrone, 5-fluorouracil, cyclophosphamide) in advanced breast cancer

A multicer randomized study

V. Lorusso, P. Vici, A. R. Bianco, M. Lopez, S. De Placido, A. Piano, G. Palomba, C. Carlomagno, M. D'Aprile, V. Fosser, M. Brandi, M. De Lena

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A multicentric randomized study was conducted to compare the CNF regimen (cyclophosphamide at 600 mg/m2/iv, mitoxantrone at 10 mg/m2/iv, 5-fluorouracil at 600 mg/m2/iv) with the CMF regimen (methotrexate at 40 mg/m2/iv instead of mitoxantrone) administered every 3 weeks to previously untreated locally advanced or metastatic breast cancer patients. In 119 patients evaluable for therapeutic response, complete plus partial response rate was 44% for CNF and 29% for CMF (p > 0.05; 95% C.I.: CNF = 32%-56%, CMF = 18%-40%). No statistically significant difference regarding time to progression, overall survival or response to second-line chemotherapy with Epidoxorubicin was observed between the two regimens. Both regimens were well tolerated, but the percent of alopecia and leucopenia was significantly higher in the CNF patient group (31% versus 5% and 18% versus 0%, respectively; p <0.01). In conclusion, CNF was demonstrated to be slightly more toxic but more effective as compared to CMF (global response: 44% versus 29%, respectively). These findings should be taken into consideration when planning future studies of adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)531-535
Number of pages5
JournalInternational Journal of Oncology
Volume2
Issue number4
Publication statusPublished - 1993

Fingerprint

Mitoxantrone
Combination Drug Therapy
Methotrexate
Fluorouracil
Cyclophosphamide
Breast Neoplasms
Poisons
Alopecia
Leukopenia
Adjuvant Chemotherapy
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research

Cite this

Combination chemotherapy withy CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (mitoxantrone, 5-fluorouracil, cyclophosphamide) in advanced breast cancer : A multicer randomized study. / Lorusso, V.; Vici, P.; Bianco, A. R.; Lopez, M.; De Placido, S.; Piano, A.; Palomba, G.; Carlomagno, C.; D'Aprile, M.; Fosser, V.; Brandi, M.; De Lena, M.

In: International Journal of Oncology, Vol. 2, No. 4, 1993, p. 531-535.

Research output: Contribution to journalArticle

Lorusso, V. ; Vici, P. ; Bianco, A. R. ; Lopez, M. ; De Placido, S. ; Piano, A. ; Palomba, G. ; Carlomagno, C. ; D'Aprile, M. ; Fosser, V. ; Brandi, M. ; De Lena, M. / Combination chemotherapy withy CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (mitoxantrone, 5-fluorouracil, cyclophosphamide) in advanced breast cancer : A multicer randomized study. In: International Journal of Oncology. 1993 ; Vol. 2, No. 4. pp. 531-535.
@article{68e16bade7a44f9c9f4ac6c7a1401857,
title = "Combination chemotherapy withy CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (mitoxantrone, 5-fluorouracil, cyclophosphamide) in advanced breast cancer: A multicer randomized study",
abstract = "A multicentric randomized study was conducted to compare the CNF regimen (cyclophosphamide at 600 mg/m2/iv, mitoxantrone at 10 mg/m2/iv, 5-fluorouracil at 600 mg/m2/iv) with the CMF regimen (methotrexate at 40 mg/m2/iv instead of mitoxantrone) administered every 3 weeks to previously untreated locally advanced or metastatic breast cancer patients. In 119 patients evaluable for therapeutic response, complete plus partial response rate was 44{\%} for CNF and 29{\%} for CMF (p > 0.05; 95{\%} C.I.: CNF = 32{\%}-56{\%}, CMF = 18{\%}-40{\%}). No statistically significant difference regarding time to progression, overall survival or response to second-line chemotherapy with Epidoxorubicin was observed between the two regimens. Both regimens were well tolerated, but the percent of alopecia and leucopenia was significantly higher in the CNF patient group (31{\%} versus 5{\%} and 18{\%} versus 0{\%}, respectively; p <0.01). In conclusion, CNF was demonstrated to be slightly more toxic but more effective as compared to CMF (global response: 44{\%} versus 29{\%}, respectively). These findings should be taken into consideration when planning future studies of adjuvant chemotherapy.",
author = "V. Lorusso and P. Vici and Bianco, {A. R.} and M. Lopez and {De Placido}, S. and A. Piano and G. Palomba and C. Carlomagno and M. D'Aprile and V. Fosser and M. Brandi and {De Lena}, M.",
year = "1993",
language = "English",
volume = "2",
pages = "531--535",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Combination chemotherapy withy CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (mitoxantrone, 5-fluorouracil, cyclophosphamide) in advanced breast cancer

T2 - A multicer randomized study

AU - Lorusso, V.

AU - Vici, P.

AU - Bianco, A. R.

AU - Lopez, M.

AU - De Placido, S.

AU - Piano, A.

AU - Palomba, G.

AU - Carlomagno, C.

AU - D'Aprile, M.

AU - Fosser, V.

AU - Brandi, M.

AU - De Lena, M.

PY - 1993

Y1 - 1993

N2 - A multicentric randomized study was conducted to compare the CNF regimen (cyclophosphamide at 600 mg/m2/iv, mitoxantrone at 10 mg/m2/iv, 5-fluorouracil at 600 mg/m2/iv) with the CMF regimen (methotrexate at 40 mg/m2/iv instead of mitoxantrone) administered every 3 weeks to previously untreated locally advanced or metastatic breast cancer patients. In 119 patients evaluable for therapeutic response, complete plus partial response rate was 44% for CNF and 29% for CMF (p > 0.05; 95% C.I.: CNF = 32%-56%, CMF = 18%-40%). No statistically significant difference regarding time to progression, overall survival or response to second-line chemotherapy with Epidoxorubicin was observed between the two regimens. Both regimens were well tolerated, but the percent of alopecia and leucopenia was significantly higher in the CNF patient group (31% versus 5% and 18% versus 0%, respectively; p <0.01). In conclusion, CNF was demonstrated to be slightly more toxic but more effective as compared to CMF (global response: 44% versus 29%, respectively). These findings should be taken into consideration when planning future studies of adjuvant chemotherapy.

AB - A multicentric randomized study was conducted to compare the CNF regimen (cyclophosphamide at 600 mg/m2/iv, mitoxantrone at 10 mg/m2/iv, 5-fluorouracil at 600 mg/m2/iv) with the CMF regimen (methotrexate at 40 mg/m2/iv instead of mitoxantrone) administered every 3 weeks to previously untreated locally advanced or metastatic breast cancer patients. In 119 patients evaluable for therapeutic response, complete plus partial response rate was 44% for CNF and 29% for CMF (p > 0.05; 95% C.I.: CNF = 32%-56%, CMF = 18%-40%). No statistically significant difference regarding time to progression, overall survival or response to second-line chemotherapy with Epidoxorubicin was observed between the two regimens. Both regimens were well tolerated, but the percent of alopecia and leucopenia was significantly higher in the CNF patient group (31% versus 5% and 18% versus 0%, respectively; p <0.01). In conclusion, CNF was demonstrated to be slightly more toxic but more effective as compared to CMF (global response: 44% versus 29%, respectively). These findings should be taken into consideration when planning future studies of adjuvant chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0027178325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027178325&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 531

EP - 535

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -